Request Sample Inquiry
Hemophilia Market

Hemophilia Market

Hemophilia Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

183

Base Year:

2022

Date

Jan - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1216

Segments Covered
  • By Type By Type Hemophilia A, Hemophilia B, Hemophilia C, Others
  • By Treatment By Treatment On-demand, Prophylaxis
  • By Therapy By Therapy Replacement therapy, ITI therapy, Gene therapy
  • By Region By Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 12.61 Billion
Revenue 2030Revenue 2030: USD 18.77 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 5.10%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Hemophilia Market - Segment Analysis
    1. Overview
    2. Global Hemophilia Market, 2016 - 2028 (USD Million)
    3. Global Hemophilia Market - by Type
      1. By Hemophilia A
      2. By Hemophilia B
      3. By Hemophilia C
      4. By Others
    4. Global Hemophilia Market - by Treatment
      1. By On-demand
      2. By Prophylaxis
    5. Global Hemophilia Market - by Therapy
      1. By Replacement therapy
      2. By ITI therapy
      3. By Gene therapy
    6. Global Hemophilia Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America Hemophilia Market - Segment Analysis
    1. Overview
    2. North America Hemophilia Market, 2016 - 2028 (USD Million)
    3. North America Hemophilia Market, by Type
      1. By Hemophilia A
      2. By Hemophilia B
      3. By Hemophilia C
      4. By Others
    4. North America Hemophilia Market, by Treatment
      1. By On-demand
      2. By Prophylaxis
    5. North America Hemophilia Market, by Therapy
      1. By Replacement therapy
      2. By ITI therapy
      3. By Gene therapy
    6. North America Hemophilia Market, by Country
      1. U.S.
        1. U.S. Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. U.S. Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. U.S. Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      2. Canada
        1. Canada Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Canada Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Canada Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      3. Mexico
        1. Mexico Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Mexico Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Mexico Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
  5. Europe Hemophilia Market - Segment Analysis
    1. Overview
    2. Europe Hemophilia Market, 2016 - 2028 (USD Million)
    3. Europe Hemophilia Market, by Type
      1. By Hemophilia A
      2. By Hemophilia B
      3. By Hemophilia C
      4. By Others
    4. Europe Hemophilia Market, by Treatment
      1. By On-demand
      2. By Prophylaxis
    5. Europe Hemophilia Market, by Therapy
      1. By Replacement therapy
      2. By ITI therapy
      3. By Gene therapy
    6. Europe Hemophilia Market, by Country
      1. Germany
        1. Germany Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Germany Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Germany Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      2. UK
        1. UK Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. UK Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. UK Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      3. France
        1. France Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. France Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. France Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      4. Spain
        1. Spain Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Spain Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Spain Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      5. Italy
        1. Italy Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Italy Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Italy Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      6. BENELUX
        1. BENELUX Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. BENELUX Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. BENELUX Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      7. Rest of Europe
        1. Rest Of Europe Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Rest Of Europe Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Rest Of Europe Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
  6. Asia Pacific Hemophilia Market - Segment Analysis
    1. Overview
    2. Asia Pacific Hemophilia Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Hemophilia Market, by Type
      1. By Hemophilia A
      2. By Hemophilia B
      3. By Hemophilia C
      4. By Others
    4. Asia Pacific Hemophilia Market, by Treatment
      1. By On-demand
      2. By Prophylaxis
    5. Asia Pacific Hemophilia Market, by Therapy
      1. By Replacement therapy
      2. By ITI therapy
      3. By Gene therapy
    6. Asia Pacific Hemophilia Market, by Country
      1. China
        1. China Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. China Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. China Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      2. Japan
        1. Japan Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Japan Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Japan Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      3. India
        1. India Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. India Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. India Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      4. South Korea
        1. South Korea Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. South Korea Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. South Korea Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      5. South East Asia
        1. South East Asia Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. South East Asia Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. South East Asia Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Rest of Asia Pacific Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Rest of Asia Pacific Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
  7. Latin America Hemophilia Market - Segment Analysis
    1. Overview
    2. Latin America Hemophilia Market, 2016 - 2028 (USD Million)
    3. Latin America Hemophilia Market, by Type
      1. By Hemophilia A
      2. By Hemophilia B
      3. By Hemophilia C
      4. By Others
    4. Latin America Hemophilia Market, by Treatment
      1. By On-demand
      2. By Prophylaxis
    5. Latin America Hemophilia Market, by Therapy
      1. By Replacement therapy
      2. By ITI therapy
      3. By Gene therapy
    6. Latin America Hemophilia Market, by Country
      1. Brazil
        1. Brazil Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Brazil Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Brazil Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      2. Argentina
        1. Argentina Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Argentina Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Argentina Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      3. Rest of Latin America
        1. Rest of Latin America Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Rest of Latin America Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Rest of Latin America Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
  8. Middle East & Africa Hemophilia Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Hemophilia Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Hemophilia Market, by Type
      1. By Hemophilia A
      2. By Hemophilia B
      3. By Hemophilia C
      4. By Others
    4. Middle East & Africa Hemophilia Market, by Treatment
      1. By On-demand
      2. By Prophylaxis
    5. Middle East & Africa Hemophilia Market, by Therapy
      1. By Replacement therapy
      2. By ITI therapy
      3. By Gene therapy
    6. Middle East & Africa Hemophilia Market, by Country
      1. GCC Countries
        1. GCC Countries Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. GCC Countries Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. GCC Countries Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      2. South Africa
        1. South Africa Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. South Africa Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. South Africa Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Hemophilia Market, By Type
          1. By Hemophilia A
          2. By Hemophilia B
          3. By Hemophilia C
          4. By Others
        2. Rest of Middle East & Africa Hemophilia Market, By Treatment
          1. By On-demand
          2. By Prophylaxis
        3. Rest of Middle East & Africa Hemophilia Market, By Therapy
          1. By Replacement therapy
          2. By ITI therapy
          3. By Gene therapy
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Shire (Baxalta); CSL Behring; Pfizer Inc.; Bayer AG; BioMarin
    2. Spark Therapeutics Inc.; Genzyme Corporation; Chugai Pharmaceutical Co. Ltd.; Novo Nordisk A/S.; and Octapharma AG
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 30-Jan-2022
Hemophilia Market to Reach Valuation of USD 14.2 Billion By 2028 - Increasing Focus on Prophylactic Treatment and Increasing Consumer Healthcare Expenditure to Flourish Market
FAQ
Frequently Asked Question

  • The global Hemophilia valued at USD 12.61 Billion in 2022 and is expected to reach USD 18.77 Billion in 2030 growing at a CAGR of 5.10%.

  • The prominent players in the market are Shire (Baxalta); CSL Behring; Pfizer, Inc.; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Genzyme Corporation; Chugai Pharmaceutical Co. Ltd.; Novo Nordisk A/S.; and Octapharma AG.

  • The market is project to grow at a CAGR of 5.10% between 2023 and 2030.

  • The driving factors of the Hemophilia include

    • Growing Prevalence of Hemophilia

  • North America was the leading regional segment of the Hemophilia in 2022.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy